Synonyms: EXAMPLE 2 [WO2014102818A1] | Oxemia® | ZYAN-1 | ZYAN1
Compound class:
Synthetic organic
Comment: Desidustat (ZYAN1) is an orally bioavailable inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzymes (PHD1, PHD2, and PHD3; genes EGLN2, EGLN1 and EGLN3 respectively) [5]. It was developed as a strategy to promote erythropoietin (EPO) synthesis and erythropoiesis by stabilising HIF-α transcription factors, as a mechanism to treat anemia associated with chronic diseases. Orally active HIF-PH inhibitors are being exploited as alternatives to injectable erythropoietin stimulating drugs, such as epoetin and darbepoetin, to treat anemia.
|
|
No information available. |
Summary of Clinical Use ![]() |
Desidustat (ZYAN1) was advanced to clinical studies to evaluate its potential as a treatment for anemia in patients with chronic kidney disease and chemotherapy-induced anemia. First approval of desidustat was granted in India in March 2022 [3], as a treatment for chronic kidney disease-induced anaemia. Desidustat has also been tested for efficacy as a pharmacological intervention for anaemia associated with COVID-19. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04463602 | Desidustat in the Management of COVID-19 Patients | Phase 2 Interventional | Zydus Lifesciences Limited | ||
NCT04667533 | Desidustat in the Treatment of Chemotherapy Induced Anemia | Phase 1 Interventional | Zydus Lifesciences Limited | ||
NCT04012957 | Desidustat in the Treatment of Anemia in CKD | Phase 3 Interventional | Zydus Lifesciences Limited | The DREAM-ND study | 1 |
NCT04215120 | Desidustat in the Treatment of Anemia in CKD on Dialysis Patients | Phase 3 Interventional | Zydus Lifesciences Limited | The DREAM-D study | 4 |